The Food and Drug Administration (FDA) has approved Arbli™, an oral suspension formulation of losartan potassium. Arbli, an angiotensin II receptor blocker, is indicated for the treatment of ...
Generic drugmakers and hospital pharmacists warn that added financial pressure from tariffs could strain the nation's generic drug supplies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback